Galderma Group AG
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable
- Conditions
- Interventions
- First Posted Date
- 2021-09-27
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Galderma R&D
- Registration Number
- NCT05056779
A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 34
- Registration Number
- NCT05052983
- Locations
- 🇨🇭
Galderma Investigational Site 5069, Lausanne, Switzerland
🇵🇱Galderma Investigational Site 6237, Ostrowiec Świętokrzyski, Poland
🇫🇷Galderma Investigational Site 5140, Nice, France
Comparison Dry Foot Skin Between Diabetic and Non-diabetic Subjects and the Effects of Two Cosmetic Foot Care Products
- Conditions
- Interventions
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 60
- Registration Number
- NCT05046015
- Locations
- 🇩🇪
Charité Universitatsmedizin Berlin, Berlin, Germany
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 105
- Registration Number
- NCT04921345
- Locations
- 🇵🇱
Galderma Investigational Site #6261, Wrocław, Poland
🇺🇸Galderma Investigational Site #8560, West Bloomfield, Michigan, United States
🇺🇸Galderma Investigational Site #9930, Vista, California, United States
Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation
- Conditions
- Interventions
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 121
- Registration Number
- NCT04856904
- Locations
- 🇺🇸
Galderma Investigational Site #8447, Fort Smith, Arkansas, United States
🇺🇸Galderma Investigational Site #8608, Santa Monica, California, United States
🇺🇸Galderma Investigational Site #8881, Stony Brook, New York, United States
A Study to Evaluate the Effectiveness and Safety of GAL1906 for Correction of Wrinkles in the décolletage Area
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 192
- Registration Number
- NCT04717934
- Locations
- 🇺🇸
Galderma Research Site, Mequon, Wisconsin, United States
Study to Evaluate Satisfaction After Treatment With Restylane
- Conditions
- Interventions
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 60
- Registration Number
- NCT04638816
- Locations
- 🇨🇦
Galderma Study Site, Montreal, Quebec, Canada
New Dermal Filler for Chin Correction and Augmentation
- Conditions
- Interventions
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 140
- Registration Number
- NCT04631263
- Locations
- 🇨🇦
Galderma Research Site, Westmount, Quebec, Canada
Open Label Extension for 43USSA1812
- Conditions
- Interventions
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 110
- Registration Number
- NCT04595331
- Locations
- 🇺🇸
Galderma Research Site, Spring, Texas, United States
🇺🇸Galderma Research site, San Diego, California, United States
A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 17
- Registration Number
- NCT04562116
- Locations
- 🇧🇬
5952 Galderma Investigational Site, Sofia, Bulgaria
🇺🇸9954 Galderma Investigational Site, Hallandale Beach, Florida, United States
🇺🇸9923 Galderma Investigational Site, Miami, Florida, United States